Physician profile
Amber M Savell
NPI 1063883601
$1,022.05
in general payments reported to CMS, 2019-2025
18 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $160 · 2023: $117 · 2024: $181 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145.54 | 2022-2024 | |
| Amgen INC. | $125.43 | 2021-2025 | Otezla, Repatha, Evenity |
| Inspire Medical Systems, INC. | $111.76 | 2025 | Inspire |
| Novo Nordisk INC | $111.22 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $107.65 | 2021-2025 | Jardiance, Trulicity, Mounjaro |
| Pfizer INC. | $75.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $52.64 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $43.51 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $40.02 | 2021-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $31.23 | 2023-2025 | |
| Axonics, INC. | $31.00 | 2024 | Axonics |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.20 | 2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $26.78 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $21.20 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.16 | 2024 | Caplyta |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.30 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $18.01 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Savell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.